Summary:
Interview Study for Adults with cytomegalovirus (CMV) after transplant
Adelphi Values, a health research organization that works with pharmaceutical companies to assess the impact of health conditions and their treatments on peoples’ lives, is conducting a study exploring the burden of cytomegalovirus (CMV) and its treatment on transplant recipients. CMV infection is common in post-transplant patients and can lead to various medical problems such as increased graft failure and mortality. Sometimes CMV lasts for a long time even if being treated with medicine, or it comes back after you and your doctors think it has gone away.
Adelphi Values is looking to speak with adults 18 years of age or older who are recipients of a solid organ transplant (SOT) or an allogenic hematopoietic stem cell transplant (HSCT) within the past five years, and have experienced CMV infection that lasted for over two weeks despite treatment, or CMV infection that came back after being treated successfully in the past. Adelphi Values invites those who have experienced this type of CMV to participate in a telephone interview. Participation in the study will consist of a brief interviewer-administered questionnaire and a one-on-one 60-minute telephone interview to discuss your experience with CMV infection, its treatment, and its impact on your life. You will receive $120 for completing the 60-minute interview.
During this study, no medication will be given or tested. Your inclusion in the interviews will not replace or affect any care or assistance you are currently receiving or may receive in the future. Your name and contact information will not be shared with anyone and will remain confidential.